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Center of Excellence, University of Virginia Health System, Charlottesville, VA, USASummary estimated 748,300 new liver cancer cases and 695,900 liver can-Hepatocellular carcinoma (HCC) is a common cancer world-
wide that primarily develops in cirrhosis resulting from chronic
infection by hepatitis B virus and hepatitis C virus, alcoholic
injury, and to a lesser extent from genetically determined disor-
ders such as hemochromatosis. HCC has recently been linked to
non-alcoholic fatty liver disease (NAFLD), the hepatic manifesta-
tion of obesity and related metabolic disorders such as diabetes.
This association is alarming due to the globally high prevalence of
these conditions and may contribute to the rising incidence of
HCC witnessed in many industrialized countries. There is also
evidence that NAFLD acts synergistically with other risk factors
of HCC such as chronic hepatitis C and alcoholic liver injury.
Moreover, HCC may complicate non-cirrhotic NAFLD with mild
or absent ﬁbrosis, greatly expanding the population potentially
at higher risk. Major systemic and liver-speciﬁc molecular mech-
anisms involved include insulin resistance and hyperinsulinemia,
increased TNF signaling pathways, and alterations in cellular lipid
metabolism. These provide new targets for prevention, early rec-
ognition, and effective treatment of HCC associated with NAFLD.
Indeed, both metformin and PPAR gamma agonists have been
associated with lower risk and improved prognosis of HCC. This
review summarizes current evidence as it pertains to the epide-
miology, pathogenesis, and prevention of NAFLD-associated HCC.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.Introduction
Liver cancer is the ﬁfth most frequently diagnosed cancer world-
wide and the third leading cause of cancer death. In 2008, anJournal of Hepatology 20
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disease.cer deaths occurred, reﬂecting the poor prognosis of this disease
[1]. HCC represents the major histological subtype of primary
liver malignancies, accounting for 70% to 85% of the total liver
cancer burden [2]. Most cases of HCC (75% to 90%) develop in cir-
rhosis resulting from chronic infection by hepatitis B virus and
hepatitis C virus, alcoholic injury, and to a lesser extent from
genetically determined disorders such as hemochromatosis [3,4].
HCC is increasingly common in the United States, with an age-
adjusted incidence rising from 1.5 to 4.9 per 100,000 individuals
in the past 30 years [5]. This worrisome trend has been primarily
attributed to the high prevalence of chronic hepatitis C in this
population and it is predicted to plateau by 2020 [6]. However,
epidemiological studies indicate that the etiology of HCC is
unclear in up to 50% of all cases, making predictions about near-
ing the peak of its incidence perhaps too optimistic [3,4].Epidemiology of HCC associated with NAFLD
HCC in obesity and diabetes
Several large-scale epidemiological studies have associated the
increasingly prevalent overweight and obesity with a higher risk
of HCC [7,8]. In a cohort of 900,000 American adults, the risk of
dying from liver cancer was 4.5 times higher in men with a body
mass index of 35 kg/m2 or above compared to the reference
group with a normal body mass index (18.5 to 24.9 kg/m2) [7].
A recent meta-analysis concluded that the summary relative risk
of liver cancer was 117% for overweight subjects and 189% for the
obese [9].
Type 2 diabetes is an increasingly commonmetabolic disorder
strongly linked to obesity and characterized by hyperglycemia,
insulin resistance, and hyperinsulinemia. It has been associated
with increased risk of several cancers [10]. Substantial evidence
indicates that diabetes promotes the development and progres-
sion of HCC [11]. A population-based study from 14% of the United
States population found that diabetes conferred a three-fold risk
of HCC [12]. In a large prospective cohort study conducted among
US veterans, diabetes was associated with a hazard rate ratio of
2.16 for HCC [13]. The association between diabetes and HCC
has been further demonstrated by studies published from differ-
ent geographical locations [14–20] and ascertained by repeated12 vol. 56 j 1384–1391
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meta-analyses [11,21]. The ﬁndings indicate that diabetes in
most individuals may exist for long time before the diagnosis of
HCC and there are synergistic interactions between diabetes
and other HCC risk factors [14–16,19,20].
HCC has been linked to NAFLD, the major hepatic manifes-
tation of obesity and associated metabolic conditions [22]. The
epidemiology of NAFLD mirrors recent changes in the preva-
lence of obesity and diabetes. NAFLD has become the most
common liver disorder in the United States and other industri-
alized countries, affecting up to 30% of the general adult pop-
ulation and 90% of those with morbid obesity (body mass
index greater than or equal to 40 kg/m2) [23,24]. The overlap
between the prevalence of NAFLD and diabetes is equally sub-
stantial. The rate of biopsy-proven NAFLD among diabetics may
reach 74% [25,26], and NAFLD is commonly associated with
insulin resistance and hyperinsulinemia even in the non-obese
[27].HCC in advanced NAFLD
While most individuals with NAFLD have isolated steatosis,
approximately 20% of all cases present as steatohepatitis,
which is microscopically deﬁned and consists of steatosis and
a speciﬁc form of hepatocellular injury, parenchymal and portal
inﬂammation, and variable degrees of ﬁbrosis with the poten-
tial to progress to cirrhosis [28,29]. The ﬁrst report on HCC
complicating NAFLD with cirrhosis was published in 1990
[30]. Subsequent studies of natural history in NAFLD indicated
that while steatosis has an almost negligible effect on liver-
related mortality [28,29], steatohepatitis is a risk for the devel-
opment of cirrhosis and HCC [31]. The exact prevalence of HCC
in cirrhotic NAFLD remains unknown. Two groups from Swe-
den described three and ﬁve cases of HCC in cohorts of 129
and 256 subjects with NAFLD followed for 13.7 and 21 years,
respectively [29,32]. In the past 10 years, approximately 300
cases of NAFLD-associated HCC have been reported [33–35].
The majority of affected patients have been men of a median
age over 70 years with diabetes and hypertension as common
co-morbidities [33–35].
Reports indicate that the risk of HCC due to NAFLD is less
than that of chronic hepatitis C. In a ten-year prospective
study, ten out of 149 American patients with NAFLD-associated
cirrhosis developed HCC compared to 25 out of 147 patients
with hepatitis C virus-associated cirrhosis [36]. Another study
from the United States found a 2.6% yearly cumulative inci-
dence of HCC in patients with NAFLD-associated cirrhosis
compared with a 4.0% incidence in those with hepatitis C
virus-associated cirrhosis over a median follow-up of 3.2 years
[37]. A prospective ﬁve-year study in Japan for the develop-
ment of HCC found a rate of 11.3% among 68 patients with
NAFLD-associated cirrhosis compared to 30.5% among 69
patients with hepatitis C virus-associated cirrhosis [38].
Nonetheless, based on its prevalence and natural history,
NAFLD in the United States and other developed countries
may become the primary source of HCC and offset the impact
of successful measures on reducing the incidence of hepatitis C
virus-related liver cancer [4]. This concern was substantiated
by a recent study from Germany analyzing 162 cases of HCC
that identiﬁed steatohepatitis as the underlying etiology in
24% of patients, surpassing chronic hepatitis C (23.3%), chronic
hepatitis B (19.3%), and alcoholic liver disease (12.7%) [34].Journal of Hepatology 2012HCC in cryptogenic cirrhosis
Current ﬁgures probably underestimate the role of NAFLD in HCC
development. NAFLD and related metabolic factors may act syn-
ergistically with other conditions to promote hepatocarcinogene-
sis. This has been suggested to occur in cirrhosis associated with
both chronic hepatitis C infection and alcoholic liver disease
[37,39]. In addition, NAFLD may remain unrecognized as the eti-
ology in cases of HCC arising in cryptogenic cirrhosis, a condition
for which no underlying etiology has been clinically identiﬁed
[40]. It is estimated that 30% to 40% of all HCCs in industrialized
countries occur in patients with cryptogenic cirrhosis [4]. Studies
suggest that the majority of these cases are associated with either
prior NAFLD or other features of the metabolic syndrome [41,42].
Sequential biopsy studies have, in fact, documented that active
steatohepatitis may eventually result in bland cirrhosis. Since
key elements of steatohepatitis such as hepatocellular lipid accu-
mulation, ballooning injury and necroinﬂammation are often
absent in cirrhosis, the diagnosis of NAFLD may be missed unless
detailed medical history reveals its prior existence [43]. Exclud-
ing a role of alcohol in these and other forms of chronic liver dis-
ease remains challenging.HCC in non-cirrhotic NAFLD
HCC has been documented to occur in livers without underlying
cirrhosis or even liver disease. In fact, up to 54% of all cases of
HCC develop in non-cirrhotic livers according to various etiolo-
gies and geographic areas [44,45]. An uncertain fraction of these
likely arise through transformation of hepatic adenomas. A liter-
ature review of over 1600 adenomas has shown that up to 4.2% of
hepatocellular adenomas harbor HCC at the time of resection
[46]. Most reported cases of non-cirrhotic HCC occur in chronic
hepatitis B attributed to the direct oncogenic properties of hepa-
titis B virus through genomic integration and the transactivation
effects of HBx protein. In Sub-Saharan Africa, dietary exposure to
aﬂatoxin may synergize with the carcinogenic effects of chronic
hepatitis B infection [47]. HCC may also arise without established
cirrhosis in 14% to 19% of patients with chronic hepatitis C infec-
tion and alcoholic liver disease, although the mechanisms of car-
cinogenesis remain unclear [44,48].
A rapidly growing literature indicates that NAFLD contributes
to non-cirrhotic HCC. Since 2004, at least 116 cases of HCC have
been reported in histologically-conﬁrmed NAFLD without cirrho-
sis (Table 1). This number represents more than one-third of all
NAFLD-associated HCC cases reported, suggesting either that
non-cirrhotic HCC may occur more commonly in NAFLD than in
liver diseases of other etiologies, or a reporting bias. Indeed, some
of these reports include cases with F3 (bridging) ﬁbrosis that may
represent sampling error or incomplete cirrhosis. Nonetheless, a
retrospective French study showed that the etiology of liver dis-
ease in 80 cases of HCC remained unknown in 50 (62%) without
portal ﬁbrosis in the background livers as opposed to only 15
out of 250 (6%) in which extensive ﬁbrosis or cirrhosis was pres-
ent [49]. Since most cases without advanced ﬁbrosis had steatosis
(52%) and portal inﬂammation (79%), the majority of patients
with HCC of unknown etiology in this series possibly had NAFLD.
More recently, the same group analyzed a subsequent cohort of
HCC patients (30 men and one woman) with the metabolic syn-
drome as the only risk factor for liver disease and found mild
or no ﬁbrosis in most cases compared to those harboring HCCvol. 56 j 1384–1391 1385
Table 1. Case reports and case series of HCC diagnosed in non-cirrhotic NAFLD.
Study, authors, [Ref.] Cases
(n)
Gender Tumor Fibrosis
(stage) 
Bencheqroun et al., (France, 2004) [104] 1 M (1) Solitary F2
Bullock et al., (UK, 2004) [105] 2 M (2) Solitary F0
Gonzalez et al., (France, 2004) [106] 1 M (1) n.r. F1
Regimbeau et al., (France, 2004) [42] 10 M (10) n.r. F2-F3
Cuadrado et al., (Spain, 2005) [107] 1 M (1) Solitary F2 
Hai et al., (Japan, 2006) [108] 1 M (1) Solitary F2 
Ichikawa et al., (Japan, 2006) [109] 2* M (1), F (1) Solitary F2-F3
Hashizume et al., (Japan, 2007) [110] 3 M (3) Solitary (2), multifocal (1) F1-F3
Guzman et al., (USA, 2008) [51] 3 M (1), F (2) Multifocal F0
Paradis et al., (France, 2009) [50] 16** M (16)*** n.r. F0-F2
Kawada et al., (Japan, 2009) [90] 6 M (3), F (3) Solitary F2-F3
Hashimoto et al., (Japan, 2009) [102] 4 n.r. Solitary (70%) F1-F2
Chagas et al., (Brazil, 2009) [111] 1 M (1) Multifocal F1
Takuma et al., (Japan, 2010) [33] 7 M (3), F (4) Solitary (5), multifocal (2) F1-F3
Ikura et al., (Japan, 2011) [112] 1 M (1) Solitary F0
Ertle et al., (Germany, 2011) [34] 10 M (83.3%) n.r. F0-F3
Yasui et al., (Japan, 2011) [35] 43 M (76.7%) Solitary (72%) F1-F3
M, male; F, female; S, solitary; M, multifocal; n.r., not reported. (See above-mentioned references for further information.)
⁄One case was a combination of HCC/cholangiocarcinoma.
⁄⁄Distribution of four cases with steatosis <5% among non-cirrhotic and cirrhotic HCC could not be determined from the published data and only 16 out of 20 reported cases
with F0–F2 ﬁbrosis are included here.
⁄⁄⁄One out of 30 patients in the entire cohort was a female, but gender-speciﬁc data for the stage of ﬁbrosis were not reported.
Reviewassociated with an overt cause of liver disease (65% vs. 26%,
p <0.0001) [50]. Of note, ﬁve of the hepatocellular carcinomas
in this series deﬁnitely arose from pre-existing inﬂammatory
(telangiectatic) adenoma [50].
The largest group of NAFLD-associated non-cirrhotic HCC to
date was recently described in a cross-sectional study from Japan.
The authors analyzed 87 cases of HCC occurring in patients with
histologically conﬁrmed steatohepatitis and found no established
cirrhosis in 43 cases [35]. Men developed HCC at a less advanced
stage of ﬁbrosis than women, and the prevalence of cirrhosis was
signiﬁcantly lower in men than in women (39% vs. 70%, p = 0.008)
[35].
HCC has also been reported to develop in patients who have
features of the metabolic syndrome and histological evidence
of NAFLD, but have neither steatohepatitis nor ﬁbrosis [51].
This observation is particularly alarming as it indicates that
hepatic steatosis alone may be complicated by the develop-
ment of HCC. Relationships between steatosis, steatohepatitis,
cirrhosis, and HCC are not necessarily linear and this pattern
possibly applies to HCC arising in non-alcoholic, non-cirrhotic
fatty liver disease (Fig. 1). Recent analysis of a US health care
claim database covering 18 million lives yearly from 2002 to
2008 found that NAFLD was the leading condition with no
other risk factor claimed for 38.2% of patients with HCC and
cirrhosis was reported in only 46% of these cases [52]. Accord-
ingly, the number of individuals with NAFLD potentially at risk
for developing HCC may be much larger than previously
thought. This presents a compelling need to understand the
pathogenesis and natural history of malignant transformation
in NAFLD and review potential strategies for HCC prevention
and surveillance in the affected population.1386 Journal of Hepatology 2012Pathogenesis of HCC associated with NAFLD
General molecular mechanisms
Similar to other cancers, development of HCC in cirrhosis is a
stepwise process following a dysplasia–carcinoma sequence that
may take several decades to evolve in chronic liver disease
[53,54]. In this setting, sustained cycles of hepatocellular destruc-
tion and compensatory proliferation in response to metabolic and
oxidative toxicity, inﬂammation, innate and adaptive immunity,
and ﬁbrosis create an environment conducive to carcinogenesis.
Genomic aberrations accumulate as chronic hepatitis evolves
through cirrhosis into HCC. Initially, epigenetic mechanisms
may lead to aberrant hypo- or hypermethylation of DNA on
CpG groups in the promoter regions and other chromosomal seg-
ments in addition to inducing cis- and transactivation and chro-
matin acetylation [55,56]. Subsequently, these epigenetic
changes lead to structural genomic lesions such as point muta-
tions, multiple allelic deletions, chromosomal gains, telomere
erosion, and telomerase reactivation [53]. A critical step in these
processes is the selection of monoclonal populations of pre-
malignant hepatocytes or progenitor cells from which HCC will
emerge [57].
The extraordinary heterogeneity of genomic aberrations in
HCC suggests that multiple regulatory pathways may be compro-
mised [58]. Indeed, hepatocarcinogenesis has been associated
with reactivation of the developmental pathways (e.g., Wnt/b-
catenin, hedgehog, and c-Met/hepatocyte growth factor), upregu-
lation of multiple growth factors (e.g., platelet-derived growth
factor, vascular endothelial growth factor, ﬁbroblast growth
factor, and transforming growth factor), and stimulation ofvol. 56 j 1384–1391
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Fig. 1. Development of HCC in NAFLD. NAFLD is closely linked to obesity and related adverse health effects such as the metabolic syndrome and type 2 diabetes. Key
components of the pathogenesis known to promote this process are listed. NAFLD may primarily manifest as steatosis, steatohepatitis, or (cryptogenic) cirrhosis due to
obesity-associated metabolic derangements or it may progress through these stages over several decades. HCC may complicate any stage of NAFLD with potential
differences in the pathobiology of non-ﬁbrotic and non-cirrhotic hepatocarcinogenesis to be fully determined. Arrows illustrate relative probabilities of disease transitions
based on current evidence.
JOURNAL OF HEPATOLOGYproliferative cell signaling cascades (e.g., mitogen-activated pro-
tein kinases, the Janus kinase/signal transducers and activators
of transcription [STAT] kinase system, and the phosphoinosi-
tide-3-kinase/Akt pathway) [53,54]. The process may be aug-
mented through inhibition of cell cycle regulators (e.g., the
retinoblastoma-1 protein) and disruption of pivotal tumor sup-
pressors (e.g., the phosphatase and tensin homolog and the pleio-
tropic p53) that would normally antagonize uncontrolled and
erroneous cell proliferation [53,54].
Complexity of hepatocarcinogenesis results in functional
redundancy and robustness that may account for the poor overall
prognosis [59]. Moreover, heterogeneous phenotypes of malig-
nant hepatocytes may reﬂect disease mechanisms that corre-
spond to different etiologies and exhibit different growth
characteristics and clinical course [54]. Speciﬁc patterns of
molecular alterations deﬁned by genomic, microRNA, and pro-
tein-based analyses may be linked to the emergence of HCC in
liver diseases of various origins [53,60]. Accordingly, the molecu-
lar signature of HCC developing in NAFLD may allow identiﬁca-
tion of speciﬁc targets for the prevention, recognition, and
treatment of HCC associated with obesity and diabetes.
Mechanisms of hepatocarcinogenesis in NAFLD
Several mechanisms may account for a tumor-promoting envi-
ronment in obesity and diabetes, distinguishing the pathogenesis
of HCC linked to NAFLD from that of viral and other etiologiesJournal of Hepatology 2012[61,62]. Obesity is characterized by a low-grade, chronic inﬂamma-
tory response implicated in increased cancer risk in general [63,64].
Adipose tissue expansion promotes the release of pro-inﬂamma-
tory cytokines providing a key element to this process [64,65].
Tumor necrosis factor (TNF) is a major adipose-derived cytokine
and a potent activator of pro-oncogenic pathways involving
NF-jB, JNK, the mammalian target of rapamycin (mTOR), and
extracellular signal-regulated kinases [61,66]. In addition, interleu-
kin-6 (IL-6) has a key role in the obesity-associated inﬂammatory
response and exerts cell proliferative and anti-apoptotic effects
through activation of its major transcriptional target, STAT3
[61,66]. The role of adipose-derived TNF and IL-6 in the develop-
ment of HCC has recently been demonstrated in an experimental
model where either dietary or genetic obesity strongly promoted
malignant liver tumor growth induced by diethyl nitrosamine in
mice if production of these cytokines and their key oncogenic
signaling pathways were intact [67].
Adipose tissue expansion promotes an adverse secretory pro-
ﬁle of adipose-derived hormones or adipokines. Adiponectin, an
abundant adipokine with potent anti-inﬂammatory effects, is
expressed at reduced levels in obesity, diabetes, and NAFLD
[68,69]. Low adiponectin levels may be insufﬁcient to suppress
endotoxin-mediated inﬂammatory signaling in Kupffer cells and
other macrophages [70], to activate adenosine monophosphate
kinase, an inhibitor of the mTOR oncogenic pathway [71], and
to control angiogenesis, a pivotal mechanism of tumor growth
[72]. In contrast, circulating levels of leptin, another majorvol. 56 j 1384–1391 1387
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adipokine, are high in NAFLD [73]. Since leptin exerts pro-inﬂam-
matory and pro-ﬁbrogenic effects by activating Kupffer cells and
stellate cells, it has been connected to disease progression in
ﬁbrotic NAFLD [74–76].
Cancer cells often exhibit increased rates of fatty acid synthe-
sis and accumulation of lipid droplets [77,78], suggesting that
increased availability of lipids in hepatocytes may provide bioen-
ergetic and structural support to the rapidly proliferating cells of
HCC. Increased expression of key genes regulating lipogenesis
correlates with cell proliferation rates and poor prognosis in
HCC [79], and lipid accumulation in hepatocytes is accompanied
by distinct patterns of expression and distribution of perilipins, a
family of lipid droplet-associated proteins [78,80]. The precise
mechanisms of altered formation and utilization of lipid droplets
in the development of HCC in NAFLD remain to be elucidated.
Lipotoxicity is deﬁned as the cellular dysfunction caused by
ectopic deposition of fat in non-adipose tissues such as the liver
[65] and may contribute to the development of HCC in NAFLD.
Accumulation of fatty acids may interfere with cellular signaling
pathways and promote oncogenic mechanisms through altered
regulation of gene transcription [81,82]. Enhanced rates of fatty
acid oxidation yield lipid peroxides and free radicals that may
cause macromolecular oxidative injury, mitochondrial dysfunc-
tion, endoplasmic reticulum stress, and apoptosis [83,84]. These
molecular events may promote the liver inﬂammatory response
and thus increase the risk for hepatocarcinogenesis.
Adipose tissue expansion, release of pro-inﬂammatory cyto-
kines, and lipotoxicity collectively promote systemic and hepatic
insulin resistance, which result in hyperinsulinemia. Both are
common features of NAFLD and have been linked to tumor devel-
opment [85,86]. Deregulated metabolic effects of insulin result in
excessive activation of proliferative cell signaling cascades that
remain responsive to insulin action and have been implicated
in the development of HCC [87]. Moreover, hyperinsulinemia
results in reduced hepatic synthesis of insulin-like growth factor
(IGF)-binding protein-1 and increased bioavailability of IGF-1,
which further promotes cellular proliferation and inhibits apop-
tosis [88]. The relative contribution of systemic insulin resistance
and liver tissue-speciﬁc molecular events to the development of
HCC in NAFLD remains incompletely understood.
HCC growth in non-cirrhotic livers
When discussing the emergence of HCC in the absence of cirrho-
sis, it is important to acknowledge that in the literature the term
‘non-cirrhotic’ pertains to a variety of histopathologic features in
the background livers ranging from the normal to the diseased
liver but with no detectable ﬁbrosis, to stages of non-cirrhotic
ﬁbrosis to incomplete cirrhosis [42]. The distinctions are likely
signiﬁcant, since the pathogenesis may differ according to the
presence or absence of underlying liver disease, and the extent
thereof. A few groups have investigated biomarkers that may dis-
tinguish the molecular pathogenesis of HCC in cirrhotic vs. non-
cirrhotic livers. For example, Paradis and colleagues found that
deregulation of the Wnt/b-catenin pathway had little role in
the development of HCC associated with the metabolic syndrome
in the absence of signiﬁcant liver ﬁbrosis [50].
HCC diagnosed in cirrhotic and non-cirrhotic livers may display
different imaging and pathological attributes such as size, differen-
tiation, and encapsulation [45,50]. When associated with NAFLD,
HCC is often moderately or well differentiated and occurs as soli-
tary large mass [42,89]. HCCs that develop in livers with mild or1388 Journal of Hepatology 2012no ﬁbrosis may share these characteristics [35,90,91]. Similarly,
HCC complicating the metabolic syndrome and arising in non-
ﬁbrotic livers often remains well differentiated despite a larger size
[50]. These imaging attributes are not necessarily speciﬁc to NAFLD
and may rather reﬂect the development of HCC in the absence of
cirrhosis, for which NAFLD seems to have preponderance [91].
Amajor step in the development of cirrhotic HCC is activation of
hepatic stellate cells. Stimulated by various forms of chronic liver
injury, these cells are primarily responsible for secreting collagen
that results in liver ﬁbrosis [92]. In addition, activated stellate cells
produce various growth factors andmay stimulate oncogenic path-
ways that contribute to the expansion and selection of neoplastic
clones of liver cells [93]. The pathogenic role of stellate cells may
be limited in non-cirrhotic HCC characterized by different growth
pattern and appearance on imaging studies such as lack of encap-
sulation. Accordingly, diminished activation of stellate cells with
delayed formation of ﬁbrotic septa may result in larger liver nod-
ules that are not obscured by extensive scarring [94].Prevention of HCC associated with NAFLD
Role of diabetes control by insulin-sensitizing therapy
Based on the overwhelming epidemiologic evidence that diabetes
overlapping with NAFLD is an independent risk factor of HCC [11–
16,19,21], effective treatment of insulin resistance and hyperinsuli-
nemia may be critical to prevent hepatocarcinogenesis in the
affected population. Several reports indicate that the use of insu-
lin-sensitizing agents in diabetes may reduce the risk of HCC
[20,95–97].Metformin improves insulin resistance through the acti-
vation of AMPK, which blocks glucose output from the liver and
boosts glucose uptake in the skeletalmuscle. In addition,metformin
has direct antiproliferative effects primarily by inhibiting themTOR
oncogenic pathway [98]. A case control study from Italy involving
610 patients with HCC of mixed etiology found an odds ratio of
0.15 for HCC in metformin-treated diabetic patients with cirrhosis
when compared to those treated with sulphonylureas or insulin
[95]. In a French observational cohort of 100 consecutive diabetic
patientswith ongoingHCV cirrhosis, the hazard ratio for developing
HCC was found to be 0.19 during a median follow-up of 5.7 years
among those treated with metformin [96]. Moreover, a case control
study from a large US cancer center reported that treatment with
metformin or the insulin-sensitizing peroxisome proliferators acti-
vated receptor-c (PPARc) agonist thiazolidinediones resulted in an
adjusted risk ratio of 0.3 for HCC among diabetics while the use of
insulin secretagogue sulfonylurea drugs was associated with a 7.1-
fold increase in HCC risk compared to non-users [97].
Insulin-sensitizing therapy may also improve the prognosis of
HCC. A recent study showed that metformin therapy is associated
with lower mortality in diabetic patients with early stage HCC
after radiofrequency ablation [99]. While current guidelines for
the management of HCC have no speciﬁc recommendations for
cases associated with NAFLD, obesity, and diabetes [100], the
use of insulin-sensitizing drugs and avoidance of treatments con-
tributing to hyperinsulinemia is likely to enhance prevention and
improve disease outcomes of HCC.
Surveillance of HCC in NAFLD
The prognosis of HCC is generally poor with dismal overall
survival rates for all stages combined [2,100]. However, it isvol. 56 j 1384–1391
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encouraging that long-term survival after treatment with cura-
tive intent at early stages of the disease may now reach 50% to
70% over 5 years [101]. Further improvement in these ﬁgures is
critically linked to effective surveillance and early recognition.
For now, cirrhosis remains the primary indication for implement-
ing HCC surveillance with chronic hepatitis B as a major excep-
tion [100]. New ﬁndings on HCC in liver disease associated with
obesity and diabetes prompt some reconsideration of cancer sur-
veillance strategies, although current evidence is insufﬁcient to
allow ﬁrm recommendations. It is important to emphasize that
HCC may have a distinct pathogenesis in NAFLD, but the presence
of cirrhosis results in a substantially higher HCC incidence, as
seen in all other forms of chronic liver disease [18,102].
Cryptogenic cirrhosis certainly complicates the approach to
liver cancer surveillance [40]. Since cryptogenic cirrhosis devel-
ops insidiously, patients and caregivers may not be aware of its
presence and thus may not beneﬁt from surveillance programs
established for those diagnosed with chronic viral hepatitis or
alcoholic liver disease. This problem was well documented in a
single-center study of 105 patients with HCC, where prior histo-
logical diagnosis of steatohepatitis or clinically suspected NAFLD
was present in 47% of those with cryptogenic cirrhosis [103].
Patients with cryptogenic liver disease were less likely to be
enrolled in liver cancer surveillance (23% vs. 61%, p = 0.01), result-
ing in delayed diagnosis, larger tumor size, and diminished like-
lihood for successful therapy [103].
However, the greater dilemma comes from the new evidence
that HCC may complicate NAFLD when ﬁbrosis is mild or absent.
At one unlikely extreme, the risk of obesity-associated HCC raises
the specter of surveillance for every third adult in the United
States – the approximate prevalence of non-cirrhotic NAFLD.
Moreover, observations that diabetes may increase the risk of
HCC regardless of the presence of cirrhosis [17,18] remain a major
concern for the 26 million Americans estimated to have diabetes
or pre-diabetes. Clearly, more epidemiologic, clinical, and molec-
ular biology data are needed to determine the relative contribu-
tion of obesity, diabetes, and NAFLD to HCC and to develop a
cancer surveillance plan for the potentially affected population.
 
 
 
 
 
 
Key Points 
• HCC, a common malignancy with poor overall outcomes, 
has a rising incidence in the United States
• NAFLD, the hepatic manifestation of obesity and 
diabetes, has been linked to HCC
• NAFLD may synergize with other risk factors of HCC 
such as chronic viral hepatitis C and alcoholic liver injury 
• Insulin resistance and lipotoxicity are distinct molecular 
mechanisms that may promote development of HCC 
diagnostic and therapeutic targets
• HCC not infrequently develops in non-cirrhotic NAFLD, 
which may delay its recognition, greatly expand the 
population at increased risk, and prompt alternative 
surveillance strategies
in NAFLD, affect risk stratification, and provide newConclusions
NAFLD, by itself and in synergy with other risk factors, is becom-
ing the most common cause of HCC in developed countries. AsJournal of Hepatology 2012the global prevalence of obesity and diabetes is increasing, other
parts of the world are likely to follow suit. To make things more
difﬁcult, a considerable number of NAFLD-associated HCC cases
develop in non-cirrhotic livers. Thus, we may need to contem-
plate a paradigm shift in liver cancer surveillance. Fortunately,
there is still some good news. For now at least, HCC appears to
be a rare complication of NAFLD in the complete absence of ﬁbro-
sis. In addition, the prognosis of HCC is signiﬁcantly better with-
out cirrhosis [100]. Since ﬁbrosis in NAFLD is linked to
steatohepatitis, reliable distinction from steatosis alone by liver
biopsy or, preferably, emerging non-invasive biomarkers will
identify those at risk of disease progression and in need of cancer
surveillance. Better understanding of molecular pathways that
accelerate hepatocarcinogenesis in obesity and diabetes as well
as mapping of the molecular carcinoma sequence in a non-cir-
rhotic background will facilitate these efforts and provide new
diagnostic and therapeutic targets. Nonetheless, prevention of
obesity, diabetes, and NAFLD remain the best long-term strategy.Conﬂict of interest
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